Full Text View
Tabular View
No Study Results Posted
Related Studies
Ozone and Rhinovirus-Induced Disease in Asthmatics
This study has been completed.
Study NCT00013715   Information provided by National Institute of Environmental Health Sciences (NIEHS)
First Received: March 28, 2001   Last Updated: August 8, 2008   History of Changes
This Tabular View shows the required WHO registration data elements as marked by

March 28, 2001
August 8, 2008
September 1999
 
 
Complete list of historical versions of study NCT00013715 on ClinicalTrials.gov Archive Site
 
 
 
Ozone and Rhinovirus-Induced Disease in Asthmatics
 

In the U.S., morbidity associated with human rhinovirus (RV) infection represents a major health problem. In asthmatics, up to 80% of asthma exacerbations are associated with upper respiratory infections. Despite evidence that environmental oxidant pollutants, such as ozone, may increase the severity of viral disease, the mechanisms underlying such an effect have not been identified. This study will test the hypothesis that exposure of allergic asthmatic subjects to ambient levels of ozone directly enhances viral disease by increasing infectivity and intensifying virus-induced inflammation.

In mild asthmatics, the study will investigate: (1) if exposure to ozone will enhance the viral infective process in the nasal epithelium, (2) the effect of ozone exposure on RV-induced inflammatory gene expression, mediator release and inflammatory cell influx into the upper and lower airways, and (3) the interactive effects of ozone and RV on airway reactivity. This information will improve our understanding of the risk associated with oxidant pollutant exposure in this population of individuals in whom RV infection may represent a significant health concern.

 
Observational
Prospective
Asthma
 
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
60
August 2003
 

Subjects recruited will be non-asthmatic controls or mild allergic asthmatics using beta-agonists, mostly on an "as needed" basis. Selection criteria will include good general health by medical history and physical examination, no history of smoking, and the absence of respiratory infection in the preceding 6 week period. Subjects will undergo serologic testing and must have a negative test for neutralizing antibodies to RV16 to participate in all but one study of the project.

Both
18 Years to 45 Years
Yes
 
United States
 
 
NCT00013715
 
 
National Institute of Environmental Health Sciences (NIEHS)
 
 
National Institute of Environmental Health Sciences (NIEHS)
August 2008

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.